Drugs / AMS2434
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06604065 | Mar 2026 | Parkinson disease | University of Arkansas | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMS2434 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06604065 ↗ |
| Modality | Other / unclassified | “We have developed an EAA-based nutritional supplement called AMS2434” NCT06604065 ↗ |
| Route | Oral | “Study products will be in powder form and packaged in individual serving sizes and will be dissolved in 8 oz water for consumption.” NCT06604065 ↗ |